BeOne Medicines AG
ONC
$315.07
$4.321.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.17% | 32.06% | 40.42% | 41.56% | 47.48% |
| Total Other Revenue | 198.42% | 121.96% | 111.86% | -- | -- |
| Total Revenue | 35.46% | 32.84% | 41.00% | 41.56% | 48.64% |
| Cost of Revenue | 1.34% | -11.30% | 15.28% | 19.17% | 32.07% |
| Gross Profit | 41.37% | 40.16% | 46.28% | 45.47% | 51.95% |
| SG&A Expenses | 20.86% | 10.03% | 16.21% | 21.23% | 7.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.23% | 8.77% | 11.35% | 18.44% | 9.20% |
| Operating Income | 2,150.96% | 332.97% | 235.63% | 182.01% | 104.25% |
| Income Before Tax | 1,140.26% | 274.86% | 249.70% | 193.99% | 108.59% |
| Income Tax Expenses | 62.29% | 24.36% | -3.14% | -63.90% | 154.14% |
| Earnings from Continuing Operations | 17,802.13% | 143.79% | 202.88% | 178.34% | 100.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17,802.13% | 143.79% | 202.88% | 178.34% | 100.51% |
| EBIT | 2,150.96% | 332.97% | 235.63% | 182.01% | 104.25% |
| EBITDA | 577.00% | 822.86% | 496.46% | 241.18% | 118.01% |
| EPS Basic | 17,118.49% | 142.02% | 198.86% | 175.71% | 100.49% |
| Normalized Basic EPS | 988.00% | 331.38% | 256.39% | 194.24% | 109.14% |
| EPS Diluted | 17,005.26% | 136.29% | 188.89% | 166.67% | 100.46% |
| Normalized Diluted EPS | 983.97% | 322.05% | 250.51% | 190.69% | 108.79% |
| Average Basic Shares Outstanding | 3.77% | 4.21% | 4.07% | 3.46% | 2.55% |
| Average Diluted Shares Outstanding | 4.14% | 8.58% | 8.13% | 7.51% | 6.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |